Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 1.07% | 200.80 | 1.3% | $462.93m | |
| BIIB | Biogen Inc. | 0.09% | 223.21 | 1.3% | $371.70m | |
| GILD | Gilead Sciences, Inc. | -0.09% | 63.93 | 0.9% | $362.66m | |
| CELG | Celgene Corporation | 0.76% | 100.57 | 1.3% | $359.89m | |
| ILMN | Illumina, Inc. | 1.48% | 302.58 | 3.5% | $282.38m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.81% | 300.77 | 2.6% | $210.74m | |
| EXAS | Exact Sciences Corporation | 2.19% | 92.50 | 24.1% | $193.04m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.29% | 172.41 | 1.9% | $181.51m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.92% | 99.25 | 2.0% | $176.54m | |
| A | Agilent Technologies, Inc. | 1.77% | 75.31 | 1.6% | $166.98m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.39% | 83.48 | 14.6% | $138.14m | |
| ALDR | Alder Biopharmaceuticals, Inc. | -0.05% | 18.87 | 10.2% | $125.33m | |
| BMRN | BioMarin Pharmaceutical Inc. | 1.29% | 67.36 | 4.3% | $96.05m | |
| ACAD | ACADIA Pharmaceuticals Inc. | 0.10% | 40.52 | 13.4% | $95.97m | |
| INCY | Incyte Corporation | 0.46% | 76.12 | 2.5% | $87.99m |
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.